Cost evolution of biological drugs in rheumatoid arthritis patients in a tertiary hospital: Influential factors on price Mariángeles González Fernández, Elena Villamañán, Inmaculada Jiménez-Nácher, Francisco Moreno, Chamaida Plasencia, Francisco Gayá, Alicia Herrero, Alejandro Balsa

Costs of the standard rheumatology care in active rheumatoid arthritis patients seen in a tertiary care center in Mexico City Blanca Hernández-Cruz, Rafael Ariza-Ariza, Mario H. Cardiel-Ríos

The impact of COVID-19 and other factors on the usage status of the biologic drug therapies for rheumatoid arthritis: A study from Vietnam Hai-Binh Bui, Hong-Thinh Lai, Thanh-Lam Nguyen, Thuy-Duong Vu, Nhat-Le Bui, Van-Hung Nguyen, Thi-To-Chau Tran, Thi-Phuong-Thuy Nguyen, Thi-Ngoc-Lan Nguyen, Jaffar A. Al-Tawfiq, Dinh-Toi Chu